Asston Pharmaceuticals share news, announcements and annual reports
BSE: 544445Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 28 Oct 2026. Previous close ₹141.08.
28 Oct: open ₹140.50, high ₹148.00, low ₹140.50
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹160 Cr3,188th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 308.99
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹3.35 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 41.33
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 1.3%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹3.35 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 9.9%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −2.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.13
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 50,000
Asston Pharmaceuticals has 84 announcements on record, routine notices left out; 7 in the 30 days to 29 Oct 2026, the latest on 13 Oct 2026.
Last results date
The last board meeting held for results; the company has not yet given notice of the next.Asston Pharmaceuticals half-yearly results
The board met on 29 May 2026 to consider audited results
Notice filed 21 May 2026
Asston Pharmaceuticals annual reports, presentations and earnings calls
The company's own documents, latest first.Asston Pharmaceuticals financials, year by year
Annual reports2
- Annual report, year to Mar 20267 Sep 2026
- Annual report, 20256 Sep 2025
Asston Pharmaceuticals share news and announcements
Newest first. Page 1 of 2.
Oct 2026
13 Oct · Announcement under Regulation 30 (LODR)-Change in Registered Office Address
13 Oct · Board meeting
6 Oct · Board meeting
Meeting on 13 Oct 20261 Oct · Management
1 Oct · Management
1 Oct · Meeting
Sep 2026
29 Sep · Meeting
5 Sep · Announcement under Regulation 30 (LODR)-Allotment
5 Sep · Board meeting
4 Sep · Announcement under Regulation 30 (LODR)-Meeting Updates
4 Sep · Management
4 Sep · Management
4 Sep · Board meeting
Aug 2026
27 Aug · Board meeting
Meeting on 4 Sep 2026: annual general meeting
Jul 2026
2 Jul · Announcement under Regulation 30 (LODR)-Meeting Updates
2 Jul · Board meeting
2 Jul · Business
2 Jul · Board meeting
Jun 2026
24 Jun · Board meeting
Meeting on 2 Jul 2026: preferential issue of shares
May 2026
29 May · Results
21 May · Board meeting
Meeting on 29 May 2026: audited results
Apr 2026
Mar 2026
30 Mar · Management
30 Mar · Announcement under Regulation 30 (LODR)-Meeting Updates
30 Mar · Board meeting
25 Mar · Board meeting
Meeting on 30 Mar 2026
Feb 2026
7 Feb · Board meeting
How the price met the news
The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.
- 1 Oct 2026Board or managers changeddown 0.10%+0.9 pts vs Nifty 500market median 0.0% · five sessions −3.5% (−1.5 pts vs Nifty 500) · volume 0.2× usual · The announcement
- 7 Sep 2026Board or managers changedup 4.23%+4.7 pts vs Nifty 500market median 0.0% · five sessions −0.9% (+0.8 pts vs Nifty 500) · volume 0.4× usual · The announcement
- 1 Apr 2026Board or managers changedup 7.95%+6.0 pts vs Nifty 500market median 0.0% · five sessions +20.5% (+12.5 pts vs Nifty 500) · volume 1.1× usual · The announcement
- 4 Mar 2026Board or managers changeddown 5.46%−3.6 pts vs Nifty 500market median 0.0% · five sessions +2.5% (+4.7 pts vs Nifty 500) · volume 1.3× usual · The announcement
- 30 Jan 2026Board or managers changedup 1.99%+2.2 pts vs Nifty 500market median 0.0% · five sessions −1.7% (−3.4 pts vs Nifty 500) · volume 2.8× usual · The announcement
- 14 Oct 2025Board or managers changeddown 1.63%−1.2 pts vs Nifty 500market median 0.0% · five sessions −6.1% (−7.9 pts vs Nifty 500) · volume 0.9× usual · The announcement
- 2 Sep 2025Order receivedup 3.78%+3.7 pts vs Nifty 500market median +1.1% · five sessions +5.3% (+4.5 pts vs Nifty 500) · volume 2.3× usual · The announcement
- 31 Jul 2025Order receivedup 1.14%+1.7 pts vs Nifty 500market median +1.1% · five sessions +1.0% (+2.6 pts vs Nifty 500) · The announcement
- 23 Jul 2025Order receiveddown 2.65%−3.1 pts vs Nifty 500market median +1.1% · five sessions +4.2% (+5.5 pts vs Nifty 500) · The announcement